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Abstract 
Background: Cognitive impairment is considered a central feature of schizophrenia (SZ) and several 
rehabilitation treatments have been developed to try to improve cognitive deficits. The aim of the 
present study was to analyze the effectiveness of Integrated Psychological Therapy (IPT) compared 
with a standard treatment (TAU) in two groups of patients with SZ, using a comprehensive testing 
battery of clinical, cognitive, social cognition and functional outcome domains. 
Methods: Fourty-one patients with SZ were assigned to IPT or TAU groups in a randomized 
controlled trial (RCT). Psychopathological, neuropsychological, emotional and functional outcome 
variables were assessed at baseline and after 52 weeks of treatment. 
Results: The IPT group showed significant improvements than the TAU group regarding clinical and 
functional outcome variables. Besides, the IPT group improved significantly in the cognitive domains 
and emotional functioning. Finally, linear regression has highlighted that the improvement of 
cognitive variables depends on having done the IPT treatment. 
Conclusions: According to our data, the initial hypothesis is validated. In fact, IPT seems to be 
effective in improving clinical, neuropsychological, emotional and functional outcome in chronic SZ 
inpatients. Further studies would be desirable to deepen the effectiveness of IPT in the field of the 
psychiatric rehabilitation pointing to the possibility of recovery from mental illness.  
 
Keywords: Schizophrenia, Rehabilitation, IPT, Cognitive function, Functional outcome, Social 
cognition. 
 
 
 
 
 
 
Title 
Effectiveness of Integrated Psychological Therapy on clinical, neuropsychological, emotional and 
functional outcome in schizophrenia: a RCT study. 
 
1. Introduction 
Schizophrenia (SZ) is a chronic, cognitive and heterogeneous clinical syndrome that seems 
to originate from interruption of brain development caused by environmental or genetic factors, or 
both (Owen et al., 2016).  
The evidence of the important role played by cognitive disorders (Schulz and Murray, 2016; 
Zai et al., 2017) in the clinical definition of the patient with SZ has encouraged the emergence of 
different therapeutic programs aimed at the rehabilitation of these functions. 
Recently, pharmacological interventions have been used to achieved cognitive improvement 
but these have yielded little encouraging results in terms of functional outcome (Harvey and Sand, 
2017; Zhou et al., 2016). Other treatment strategies such as cognitive behavioral interventions (i.e. 
Cognitive Behavior Therapy, Cognitive Remediation Therapy) have demonstrated the efficacy of 
the single approach (Nowak et al., 2016; Revell et al., 2015), as well as the importance of quality of 
patient experience during rehabilitation treatment (Bassi et al., 2012). 
Integrated therapies combine some of these specific approaches. Among these interventions, 
many studies suggest that the Integrated Psychological Therapy (IPT) (Brenner et al., 1994) have 
positive effects on the cognitive outcome in SZ (Borriello et al., 2015; Roder et al., 2011; Antonio 
Vita et al., 2011). 
IPT is made up of five sub-programs and its exercises have an increasing level of difficulty. 
The first three sub-programs are aimed at basic cognitive functions (i.e. cognitive differentiation, 
social perception, verbal communication); the fourth and fifth, consisting of role-playing and 
problem solving exercises, address social and behavioral disabilities (i.e. social skills, interpersonal 
problem solving). 
The aim of the present study was to analyze the effectiveness of IPT compared with a 
standard treatment (TAU) in two groups of schizophrenic patients, using a comprehensive testing 
battery of clinical, cognitive, social cognition and functional outcome domains. We hypothesized 
that patients treated with IPT might exhibit a higher improvement in symptom reduction, 
psychosocial functioning, cognitive and social cognition functions than TAU group.  
 
2. Materials and methods 
2.1. Patients and procedures 
Patients were recruited at the rehabilitation clinic “San Vincenzo” in Catanzaro (Italy).  
All participants were deemed eligible if they were: 1) aged between 18 and 65 years and 
able to read and understand the informed consent form, 2) diagnosed with Schizophrenia according 
to the DSM-5 (American Psychiatric Association, 2013), 3) the duration of the disease was more 
than five years, 4) no relapse 6 months before the study entry, 5) in remission at the time of 
neuropsychological assessment according to a Clinical Global Impression-Schizophrenia Scale 
(CGI-SCH) (Haro et al., 2003) score ≤3, 6) participants had not previously performed IPT 
treatment, 7) free of any serious neurological or medical condition, 8) IQ >70, and 9) free of 
diagnoses of substance abuse for 6 months and dependence for 12 months. 
All participants who met the following criteria were excluded: 1) recent or uncertain 
diagnosis, 2) comorbid psychiatric diagnosis, 3) medical history that was implausible or 
undocumented, 4) drug abuse in the previous 6 months and dependence for 12 months, and 5) history 
of a medical or neurological disease that could affect cognitive function. 
Overall, 12 individuals were not eligible for the study for several reasons: 7 patients were not 
interested in participating and were illiterate and 5 participants dropped out before the conclusion of 
the treatment (3 IPT group, 2 TAU group). The final sample was made up of 41 participants and were 
consecutively recruited for this randomized controlled study. 
At the baseline (T0) the assessment of the participants was performed through the 
administration of the neuropsychiatric, neuropsychological and emotional battery to evaluate clinical 
condition, cognitive flexibility and emotional functioning in a naturalistic setting of care. 
Then, the patients were randomly divided by an independent person in the experimental group 
(Group 1, n=21), who received IPT in addition to TAU, and a control group (Group 2, n=20) with 
TAU only. The second assessment, with the same test battery administered by the same experimenter, 
was carried out after 52 weeks of intervention (T1).   
The IPT group, composed of 8–10 patients, attended treatment sessions twice a week, 45 min 
each session, for 52 weeks. They were conducted by one trained psychologist and a psychiatric 
rehabilitator who administered the 5 subprograms following the Italian version of IPT manual 
(Brenner et al., 1997). 
Participants were provided with a complete description of the study aims and methods and 
they gave informed consent to participate in the study according to the Ethical Committee before any 
procedure took place. The study, approved by the Ethical Committee of the rehabilitation clinic “San 
Vincenzo” in Catanzaro (Italy), was conducted from April 2016 to March 2017.  
 
2.2. Measures 
 
2.2.1. Clinical assessment 
 Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) was used to assess for the 
presence and severity of positive, negative and general symptoms, conceptually allocated to 
three sub-scales: seven-item scales for positive and negative symptoms and a 16-item scale 
covering general psychopathology. 
2.2.2. Functional assessment 
 
 The Global Assessment of Functioning (GAF) scale (American Psychiatric Association, 
2000) is an easy-to-use instrument utilized to rate subjectively the social, occupational, and 
psychological functioning of an individual on a hypothetical continuum of mental health-
illness, but it does not include impairment in functioning due to physical (or environmental) 
limitations.  
 World Health Organization Quality of Live (WHOQOL) (The WHOQOL Group, 1995) 
assesses individual’s perception of quality of life according to many subjective aspects such 
as physical health, psychological state, personal beliefs, social relationships and their 
relationship to salient features of his environment. 
2.2.3. Neuropsychological assessment 
All participants completed the following battery of neuropsychological tests in order to measure 
their executive functions (Liu et al., 2011) (Wang et al., 2013) (Ben-David et al., 2014): 
 The Stroop Color Word Interference Test (Golden, 1978) was administrated to evaluate visual 
and focused attention and the capacity to inhibit cognitive interference. It is divided into three 
subtests: read a list of color names, say the name of the colors that have some spots of color, 
say the name of the color in which some color names are printed (for example: if there is the 
word "green" written in yellow, it must be said "yellow").  
 The Trial Making Task (TMT) (Reitan, 1958) is divided into two parts, A and B, and it 
provides information on visual search, set-shifting and speed of processing. The test requires 
participants first to draw lines sequentially connecting 25 encircled numbers distributed then 
a 25-item alphanumeric sequence. The score on each part represents the amount of time 
required to complete the task as fast as possible.  
 The Hayling Sentence Completion Test (HSCT) (Burgess and Shallice. T., 1997) consists of 
20 sentences in which the final word is missing but is suggested by the context. Participant is 
asked to complete each sentence in either a logical (Task A, initiation task) or illogical manner 
(Task B, inhibition task) with the first word that comes to mind. Other rates provided by Task 
B are the type of answers: Type C Answer for sentence completion, Type S for semantic-
related answers and Type U for semantic-unrelated answers. The amount of the Answers S 
and C provided the error score, while the last index is the Average time of Type U answers. 
 The Wisconsin Card Sorting Test (WCST) (BERG, 1948) evaluates the executive functions 
and evaluates the perseverance and the inability to abstraction. It consists of 4 stimuli cards 
and 128 response cards with geometric figures with three features (color, form, or number) in 
various combination. The task requires subjects to find the correct classification principle by 
trial and error and examiner’s feedback. 
2.2.4. Social Cognition assessment 
Two tasks were administrated to assess the emotional functioning of participants. 
 The Reading the Mind in the Eyes (RME) (Baron-Cohen et al., 2001) evaluates an advanced 
affective Theory of Mind (ToM) task based on the patient's level of empathy that is expressed 
by the ability to understand the affective states of other people by observing only their eyes. 
The 36-item full version of the RME involves presentation of 36 photographs of the eye region 
of human faces (19 male eye pairs and 17 female): participant must choose which of the four 
options envisaged best describes the mental complex shown for each picture. 
 The Ekman 60-Faces (EK-60F) consists of a total of 60 b/w pictures selected from Ekman 
and Friesen series of Picture of Facial Affect (Ekman and Friesen, 1976), which depict the 
faces of 10 people (six women and four men), each displaying six basic emotions (i.e. surprise, 
anger, happiness, sadness, disgust and fear). Subjects is required to answer verbally choosing 
the option that best described the facial expression shown by the actor.  
 
All the neuropsychiatric, functional, neuropsychological and emotional measures were administered 
in the same session in this order: PANSS, GAF, WHOQOL, Stroop test, TMT, HSCT, WCST, RME 
and EK-60F. 
 
2.3. Statistical analysis 
Statistical Package for Social Sciences Version 21 (SPSS, Chicago, Illinois, USA) was used for data 
analysis. Descriptive statistics included frequencies and percentage, means and standard deviations, 
as appropriate. Differences between groups were explored through chi-squared and T-tests, as 
appropriate. Additionally, Cohen’s effect sizes (ES) were calculated for all significant findings, and 
values of 0.2, 0.6, 1.2, and >1.2 can be generally categorized into slight, small, moderate, and large 
ES, respectively (Cohen, 1988). Finally, linear regression analysis was performed in order to identify 
the possible clinical and socio-demographic variables related to the change of cognitive and emotional 
functioning among participants. The change on neuropsychological and social cognitive testing was 
considered as dependent variable, while clinical and demographic variables as independent 
predictors. The level of statistical significance was set at p≤0.05. 
 
3. Results 
As Table 1 shows, no differences were found regarding age, gender, level of education, duration of 
illness and mean drug dosage (chlorpromazine equivalents) between groups.  
Table 2 illustrates the results of the group’s comparison on testing battery at baseline (T0). No 
significant difference emerged in all investigated variables between groups. 
Table 3 displays the findings of the changes on the clinical, emotional, neuropsychological and 
functional assessment between groups. No significant differences were found on PANSS Positive, 
Stroop Test, RME and 4 variables of HSCT (i.e. Part A, Total errors, Type S and U Answers) between 
groups while IPT group showed significant improvement on PANSS Negative and Total, GAF, 
WHOQOL, TMT, WCST, Ek-60F, and 4 variables of HSCT (i.e. Part B, Part B-Part A, Type C 
answers and average time Type U answers) with ES that ranging from small to large (0.68-1.66) than 
TAU group.  
Finally, Table 4 shows the results of the linear regression where it is highlighted that the improvement 
of cognitive variables depends on having done the IPT treatment. 
  
4. Discussion 
The aim of this study was to evaluate the effectiveness of IPT compared with TAU group of patients 
with SZ, using a broad testing assessment of clinical, cognitive, social cognition and functional 
outcome domains. IPT treatment has amply demonstrated its effectiveness in cognitive, clinical and 
functional improvement in SZ according previous studies (Roder, 2006; Roder et al., 2011). To our 
knowledge, this is the first study where semantic inhibition and facial emotions recognition are 
assessed within the IPT. 
Regarding clinical and functional assessment, the results revealed significant differences in 
favour of IPT group in the negative and total PANSS and in the GAF and WHOQOL scales. These 
findings could be explained by the positive effect of the five IPT rehabilitation subprograms on 
overall symptoms (Mueller et al., 2013), quality of life in the psychological domain (Rakitzi et al., 
2016), socio-working and general functioning (Zimmer et al., 2007).  
Concerning neuropsychological assessment, we found significant differences in all TMT and 
WCST indexes, and in four HSCT variables and our outcomes are consistent with other authors (Vita 
et al., 2011a; Vita et al., 2011b). According to our data, IPT improves many executive functions (e.g. 
set-shifting, speed of processing) of patients with SZ evaluated through TMT and WCST, while there 
are no differences on cognitive interference inhibition, assessed by the Stroop test.  
The most striking result of our research was the improvement on HSCT, concerning cognitive 
flexibility performance, achieved after IPT treatment compared to TAU group. To the best of our 
knowledge, the present research represents the first clinical trial that assessed the effectiveness of IPT 
on cognitive flexibility and semantic inhibition using HSCT. Executive functioning impairment in 
SZ is well known and it has already been assessed using response initiation and response suppression 
latency and error rate of HSCT (Chan et al., 2012; Joshua et al., 2009), therefore our data at T0 are in 
line with the international literature. However, the novelty introduced in our work is linked to the 
great positive impact that IPT seems to have on different HSCT indices, in particular on average time 
Type U answers, with an ES of 1.66 compared to the TAU group. 
Social-cognitive impairment, characterized by difficulties in recognizing emotions relating to 
others, inferring people’s thoughts and responding emotionally to others, has been widely known in 
SZ and has been carefully studied by many authors (Green et al., 2015) and with different tools (Kalin 
et al., 2015; Rose et al., 2015). The baseline results obtained in our sample are similar to those 
described in other papers. In fact, several authors used EK-60F (Vázquez-Campo et al., 2016) or 
RME (Bora et al., 2006) or both (Balogh et al., 2014) to study social and emotional perception deficits 
in patients with SZ, demonstrating the presence of social cognition impairment in this type of patients. 
Interestingly, another novelty of the present research is represented by the impact of the IPT on EK-
60F and RME outcomes. The EK-60F showed significant differences between IPT and TAU patients 
in the total score after treatment, whereas regarding RME, the results do not reveal any significant 
differences between the two groups in the ToM ability. In other words, both groups were able to 
attribute and recognize emotional states similarly also after 52 weeks of interventions according to 
RME, but IPT group had greater capability in attributing emotional states in third person and 
recognizing others’ emotions assessed with EK-60F. These results could be explained by the 
application, in our study, of the fourth and fifth subprograms of IPT because many studies deleted 
social subprograms of IPT from the treatment (Roder et al., 2011).  
Although this study has many strengths (i.e. all the five subprograms of IPT, assessment of 
emotional functioning, IPT effect on HSCT), some limitations must be addressed. Firstly, the small 
sample size even if most IPT studies have a similar sample to ours (Roder et al., 2011). Secondly, our 
results derive from an efficacy study after treatment, while a follow-up assessment is missing to verify 
if the differences are maintained over time. Finally, related to the assessments, the MATRICS 
Consensus Cognitive Battery (MCCB) that would be the most appropriate to evaluate cognitive 
functions, has not been used because we have also investigated other domains.  
To conclude, according to our data, the initial hypothesis is confirmed. In fact, the five 
subprograms of IPT seem to be effective in improving clinical, neuropsychological, emotional and 
functional outcome in chronic SZ inpatients. It would be desirable having future studies to further 
deepen the IPT implications and fields of application as psychiatric rehabilitation technique for 
chronic patients with SZ, pointing to the possibility of recovery from mental illness (Rossi et al., 
2018; Vita et al., 2016; Zipursky and Agid, 2015). 
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 Table 1. Characteristics of the sample. 
 
  IPT group TAU group   
      test p 
Agea  50.05 (10.0) 52.14 (9.7) 0.679 .501 
Genderb Male 12 (60) 17 (81) 2.172 .141 
 Female 8 (40) 4 (19)   
Level of educationb Elementary school 3 (15) 5 (23.8) 4.123 .390 
 Middle school I 7 (35) 10 (47.6)   
 High school II 8 (40) 3 (14.3)   
 University degree 2 (10) 3 (14.3)   
Duration of illnessa (years)  22.9 (3.5) 23.4 (2.3) 0.543 .590 
Medicationa Chlorpromazine equivalents 632.4 (437.9) 674.2 (489.4) 0.288 .775 
 
 
  
Table 2. Results of neuropsychological and clinical assessment before treatment (T0). 
 
   IPT group TAU group   
   Mean SD Mean SD t Sig. 
PANSS Pos 18.1 2.5 19.5 3.1 1.587 .121 
 Neg 28.3 5.6 26.2 4.9 1.280 .208 
 Tot 90.7 11.4 92.5 9.7 .545 .589 
GAF  39.4 11.8 42.1 14.3 .658 .515 
WHOQOL  Tot 14.1 2.5 13.2 3.7 .908 .370 
TMT Part A 93.18 42.5 117.92 55.5 -1.597 .118 
 Part B 269.96 147.0 337.51 152.9 -1.440 .158 
 Part B - Part A 183.14 117.8 219.64 124.8 -.962 .342 
 Errors in Part B 1.70 1.4 2.05 2.1 -.631 .532 
WCST Global Score 49.70 36.2 65.29 34.2 -1.416 .165 
 Perseverative errors 4.55 5.4 7.38 7.7 -1.360 .182 
 Non perseverative errors 43.50 32.2 59.57 31.1 -1.624 .112 
 Failures to maintain set 1.60 2.4 .81 1.1 1.375 .177 
HSCT Part A 1.10 0.5 1.16 0.3 -.514 .610 
 Part B 4.29 2.7 4.73 0.9 -.711 .481 
 Part B - Part A 3.17 2.6 3.55 0.9 -.613 .544 
 Total errors 5.25 1.5 6.33 2.4 -1.737 .090 
 Type C answers .65 1.1 2.05 3.1 -1.894 .066 
 Type S answers 4.40 1.4 4.29 2.4 .187 .853 
 Type U answers 4.95 1.5 3.87 2.4 1.737 .090 
 Average time Type U answers 5.25 3.9 3.91 1.9 1.407 .167 
Stroop interference score -2.92 6.6 0.52 8.6 -1.441 .158 
EK-60F 34.75 13.2 29.38 10.9 -1.416 .165 
RME 14.75 4.9 12.33 3.4 -1.828 0.75 
 
 
Table 3. Comparison of changes in neuropsychological assessment between groups after treatment. 
 
  IPT group TAU group    
   Mean SD Mean SD t Sig. d 
Δ PANSS Pos -1.4 1.7 -1.9 0.4 1.311 .198  
 Neg 5.5 1.1 2.1 0.3 13.351 <.001 4.21 
 Tot 12.3 3.8 7.7 5.4  3.167 .003 0.71 
Δ GAF  -17.5 1.5 -10.3 3.1 9.389 <.001 2.96 
Δ WHOQOL Tot -1.5 1.5 -0.4 1.0 2.748 .008 0.86 
Δ TMT Part A 20.15 32.6 -9.18 25.0 3.235 .002 1.00 
 Part B 79.94 105.0 -6.55 51.5 3.374 .002 1.05 
 Part B - Part A 66.14 90.6 -2.37 35.2 3.222 .003 0.99 
 Errors in Part B .95 1.5 -.29 0.7 3.385 .002 1.06 
Δ WCST Global Score 33.35 30.6 -9.81 21.4 5.258 <.001 1.63 
 Perseverative errors 4.05 5.0 .19 0.9 3.491 .001 1.08 
 Non perseverative errors 27.65 27.1 -11.81 22.7 5.060 <.001 1.58 
 Failures to maintain set 1.15 1.7 -.67 1.5 3.645 .001 1.32 
Δ HSCT Part A -.20 1.5 -.20 0.3 .002 .998  
 Part B 1.03 1.5 -.93 0.8 4.561 <.001 1.40 
 Part B - Part A .70 1.4 -.85 1.3 3.740 .001 1.15 
 Total errors .85 2.1 .09 2.2 1.123 .268  
 Type C answers -.30 1.6 -1.5 1.9 2.167 .036 0.68 
 Type S answers .65 2.3 1.62 2.1 -1.415 .165  
 Type U answers -.35 2.5 -.09 2.2 -.349 .729  
 Average time Type U answers 1.60 1.9 -1.48 1.8 5.328 <.001 1.66 
Δ Stroop  -1.94 6.3 1.34 5.4 -1.788 .082  
Δ EK-60F -9.60 11.7 -3.48 4.6 2.210 .033 0.69 
Δ RME  -4.60 7.9 -2.86 3.4 .925 .360  
         
 
 
       
 
         
         
Table 4. Results of linear regression analysis. 
 
 Dependent variable Independent variable B t p R2 F p 
TMT Part A Treatment 31.823 3.765 .001 .306 9.802 <.001 
 Part B Treatment 86.497 3.374 .002 .206 11.383 .002 
 Errors in Part B Treatment 1.23 3.385 .002 .207 11.459 .002 
 Part B - Part A Treatment 68.518 3.222 .003 .190 10.381 .003 
WCST Global Score Treatment 43.160 5.258 <.001 .400 27.651 <.001 
 Perseverative errors Treatment 3.860 3.491 .001 0.219 12.190 .001 
 Non perseverative errors Treatment 39.460 5.060 <.001 0.381 25.604 <.001 
 Failures to maintain set Treatment 1.817 3.645 .001 0.235 13.289 .001 
HSCT Part B Treatment 1.966 4.561 <.001 0.331 20.805 <.001 
 Part B - Part A Treatment 1.554 3.740 .001 .245 13.984 .001 
 Type C answers Treatment 1.224 2.167 .036 0.085 4.695 .036 
 Average time Type U answers Treatment 3.082 5.328 <.001 .406 28.382 <.001 
EK-60F Treatment 6.124 2.210 .033 .111 4.883 .033 
 
 
